AGENDA. Risk factors for fracture in diabetes:
|
|
- Lillian Dawson
- 5 years ago
- Views:
Transcription
1
2 AGENDA Risk factors for fracture in diabetes: - Who has to be screened? - How to screen?
3 BMD AND FRACTURES IN TYPE 2 DIABETES Vestergaard P, Osteoporos Int
4 USEFULNESS OF FRAX ALGORYTHM IN TYPE 2 DIABETES
5 RISK FACTORS FOR FRAGILITY FRACTURES IN DM2 PATIENTS
6 FRATTURE E DIABETE MELLITO: RUOLO DELLE COMPLICANZE Retinopatia alterata visione Polineuropatia alterato equilibrio Cardiopatia aritmia AUMENTATO RISCHIO DI CADUTA Ipovitaminosi D
7 BIAS: more complications and hypoglycemic episodes Schwartz AV, Diabetes Care 2002
8 Hamann C et al, Nat Rev Endocrinol 2012 Hamann C et al, Nat Rev Endocrinol 2012
9 LOW BMD AND ITS PREDICTORS IN TYPE 1 DIABETIC PATIENTS EVALUATED BY ARTIFICIAL NEURAL NETWORK ANALYSIS Eller Vainicher et al, Diabetes Care 2011
10 HIGH SERUM PENTOSIDINE IS ASSOCIATED WITH PREVALENT FRACTURES IN DM1 INDEPENDENT OF BMD AND GLYCAEMIC CONTROL Neumann T et al. Osteoporos Int 2014
11 CLINICAL RISK FACTORS ASSOCIATED WITH POOR BONE HEALTH IN TYPE 1 DIABETES Zhukouskaya VV et al, J Endocrinol Invest 2015
12 SKELETAL EFFECTS OF ANTIDIABETIC AGENTS Merlotti D et al. Nutr Metab Cardiovasc Dis Positive effect Negative effect
13 EFFECTS OF ORAL HYPOGLYCEMIC AGENTS ON THE RISK OF DEVELOPING FRAGILITY FRACTURES IN T2D Palermo A et al, Osteoporos Int 2015
14 WHO HAS TO BE SCREENED? Postmenopausal women Presence of diabetic complications Cardiovascular disease Long disease duration Poor glycometabolic control High insulin doses Glitazones in postemenopausal women Other common risk factors (familiar history for fractures, low BMI, smoke, low dietary calcium intake.)
15 AGENDA Risk factors for fracture in diabetes: - Who has to be screened? - How to screen?
16 BMD AND FRACTURES IN TYPE 2 DIABETES Vestergaard P, Osteoporos Int
17 IN T2D THE FRACTURE RISK IS HIGHER FOR A GIVEN T SCORE Among older adults with type 2 DM, femoral neck BMD T score and FRAX score were associated with hip and nonspine fracture risk; however, in these patients compared with participants without DM, the fracture risk was higher for a given T score and age or for a given FRAX score. Schwartz AV et al, JAMA 2011
18 HOW TO PREDICT VERTEBRAL FRACTURES IN TYPE 2 DIABETICS? n=99 AUC 0.69, p< AUC 0.63, p<0.004 The cutoff of TBS with the best compromise between sensitivity (75.8 %) and specificity (54.1 %) is set at The cutoff of FN-BMD with the best compromise between sensitivity (70.6 %) and specificity (58.5 %) is set at less than 1.0 Zhukouskaya VV et al, Osteoporos Int 2015
19 HOW TO PREDICT VERTEBRAL FRACTURES IN TYPE 2 DIABETICS? n=99 Zhukouskaya VV et al, Osteoporos Int 2015
20 BMD AND FRACTURES IN TYPE 1 DIABETES Vestergaard P, Osteoporos Int
21 T1D PATIENTS HAVE ELEVATED PREVALENCE OF ASYMPTOMATIC VFX, REGARDLESS OF BMD Zhukouskaya VV et al, Diabetes Care 2013
22 LOW BONE TURNOVER IN DM2 Gennari L et al, JCEM 2012
23 AND HOW TO SCREEN? SIOMMMS Guidelines BMD by DXA Spinal X-ray Biochemistry Erythrocytes sedimentation rate Blood count Serum elettrophoresis Serum calcium Serum Phosphorous Alkaline Phosphatase total activity Creatinine 24 hours urinary calcium
24 TAKE HOME MESSAGES Diabetic (type 1 or 2) patients have to be screened for bone damage if hypogonadal, with diabetic complications and/or cardiovascular disease, with long disease duration and/or poor glycometabolic control and/or high insulin doses, with glitazones therapy in postmenopausal women and with other common risk factors (familiar history for fractures, low BMI, smoke, low dietary calcium intake.). Diabetic patients should undergo BMD determination by DXA and vertebral fracture risk assessment by x-ray in addition to biochemical exams.
25 THANK YOU
26 DPP4-INHIBITORS AND BONE FRACTURES: A META-ANALYSIS OF RANDOMIZED CLINICAL TRIALS (Monami M et al, Diabetes Care 2011) The duration of the trials not sufficiently long to analyse the effect on fracture. Fractures were not the principal end points and were reported only as adverse events. No data could be obtained for sexes and menopausal status. Montagnani A, Diabetes, Obesity and Metabolism 2013
27 Kohan DE et al, Kidney International 2014
28 Hamann C et al, Nat Rev Endocrinol 2012
29 WNT/ -CATENIN SIGNALLING AND REDUCED BONE TURNOVER IN T2D Gaudio A et al, JCEM 2012
30 TERIPARATIDE IS EFFECTIVE IN DIABETES Schwartz, AV et al, Bone 2016
31 ANTIRESORPTIVES AND FRACTURE RISK IN TYPE 2 DIABETES Vestergaard, Calcif Tissue Int 2011
Download slides:
Download slides: https://www.tinyurl.com/m67zcnn https://tinyurl.com/kazchbn OSTEOPOROSIS REVIEW AND UPDATE Boca Raton Regional Hospital Internal Medicine Conference 2017 Benjamin Wang, M.D., FRCPC Division
More informationOsteoporosis Screening and Treatment in Type 2 Diabetes
Osteoporosis Screening and Treatment in Type 2 Diabetes Ann Schwartz, PhD! Dept. of Epidemiology and Biostatistics! University of California San Francisco! October 2011! Presenter Disclosure Information
More informationDEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN
October 2-4, Liverpool, UK EURO SPINE 2013 DEVELOPMENT OF A RISK SCORING SYSTEM TO PREDICT A RISK OF OSTEOPOROTIC VERTEBRAL FRACTURES IN POSTMENOPAUSAL WOMEN D. Colangelo, L. A. Nasto, M. Mormando, E.
More informationBad to the Bones: Diabetes and Thiazolidinediones 9/9/2010. Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism
Bad to the Bones: Diabetes and Thiazolidinediones 9/9/2010 Steven Ing, MD, MSCE Assistant Professor Division of Endocrinology, Diabetes & Metabolism Any reduction of bone mass in diabetics that is revealed
More informationOSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO
OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et
More informationOsteoporosis/Fracture Prevention
Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team
More informationFragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey
Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone
More informationCASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS
4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending
More informationClinician s Guide to Prevention and Treatment of Osteoporosis
Clinician s Guide to Prevention and Treatment of Osteoporosis Published: 15 August 2014 committee of the National Osteoporosis Foundation (NOF) Tipawan khiemsontia,md outline Basic pathophysiology screening
More informationOsteoporosis challenges
Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1
More informationnogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK
nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,
More informationChallenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA
Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits
More informationInterpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm
Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis
More informationTreatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays. Suzanne Morin MD FRCP FACP McGill University May 2014
Treatments for Osteoporosis Expected Benefits, Potential Harms and Drug Holidays Suzanne Morin MD FRCP FACP McGill University May 2014 Learning Objectives Overview of osteoporosis management Outline efficacy
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra
More information1
www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:
More informationDisclosure and Conflicts of Interest Steven T Harris MD Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis
Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis Steven T Harris MD FACP Clinical Professor of Medicine University of California, San Francisco Disclosure and Conflicts of Interest
More informationSkeletal Manifestations
Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes
More informationBMD: A Continuum of Risk WHO Bone Density Criteria
Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris
More informationModule 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC
Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with
More informationUsing the FRAX Tool. Osteoporosis Definition
How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX
More informationDrug Intervals (Holidays) with Oral Bisphosphonates
Drug Intervals (Holidays) with Oral Bisphosphonates Rizwan Rajak Consultant Rheumatologist & Lead for Osteoporosis GP Postgraduate Meeting April 2018 Contents Case presentation Pathway for Bisphosphonate
More informationCoordinator of Post Professional Programs Texas Woman's University 1
OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies Biochemical Markers of Bone Turnover: Definitions and Recommendations for Monitoring Therapy Learning Objectives for Biochemical
More informationForteo (teriparatide) Prior Authorization Program Summary
Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis
More informationOsteoporosis: A Tale of 3 Task Forces!
Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker
More informationTask Force Co-Chairs. Members
Managing Osteoporosis Patients After Long-Term Bisphosphonate Treatment Report of a Task Force* of the American Society for Bone and Mineral Research Robert A. Adler, MD Task Force Co-Chairs Ghada El-Hajj
More informationOsteoporosis Update. Case 2. Case 1: Monday morning, 8:15
Osteoporosis Update Laura E. Ryan, MD Assistant Director for Special Programs Center for Women s Health Clinical Assistant Professor of Medicine Division of Endocrinology, Diabetes and Metabolism The Ohio
More informationGuideline for the investigation and management of osteoporosis. for hospitals and General Practice
Guideline for the investigation and management of osteoporosis for hospitals and General Practice Background Low bone density is an important risk factor for fracture. The aim of assessing bone density
More information8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview
Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology
More informationCurrent and Emerging Strategies for Osteoporosis
Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis
More informationOsteoporosis Clinical Guideline. Rheumatology January 2017
Osteoporosis Clinical Guideline Rheumatology January 2017 Introduction Osteoporosis is a condition of low bone mass leading to an increased risk of low trauma fractures. The prevalence of osteoporosis
More informationMetabolic Bone Disease Related to Chronic Kidney Disease
Metabolic Bone Disease Related to Chronic Kidney Disease Deborah Sellmeyer, MD Director, Johns Hopkins Metabolic Bone Center Dept of Medicine, Division of Endocrinology Disclosure DSMB member for denosumab
More informationDiabetes & Bone Health: A Forgotten Complication. Julie Gilmour, MBChB, FRCPC, MSc(HQ) February 6 th, 2018 Beyond The Break
Diabetes & Bone Health: A Forgotten Complication Julie Gilmour, MBChB, FRCPC, MSc(HQ) February 6 th, 2018 Beyond The Break Disclosures Relevant relationships with commercial entities None Potential for
More informationOsteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?
A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.
More informationFRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment
These guidelines are endorsed by the following Lebanese Scientific Societies and Associations: Lebanese Society of Endocrinology Diabetes and Lipids, Lebanese Society of Rheumatology, Lebanese Society
More informationPage 1. Updates in Osteoporosis. I have no conflicts of interest. What is osteoporosis? What s New in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in Osteoporosis
More informationManagement of postmenopausal osteoporosis
Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,
More informationSKELETAL FRAGILITY AND FRACTURE RISK IN PATIENTS WITH DIABETES
SKELETAL FRAGILITY AND FRACTURE RISK IN PATIENTS WITH DIABETES Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings, company owner, official role:
More informationAssessment and Treatment of Osteoporosis Professor T.Masud
Assessment and Treatment of Osteoporosis Professor T.Masud Nottingham University Hospitals NHS Trust University of Nottingham University of Derby University of Southern Denmark What is Osteoporosis? Osteoporosis
More informationUpdates in Osteoporosis. I have no conflicts of interest. What Would You Do? Mrs. C. What s New in Osteoporosis. Page 1
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationUpdates in Osteoporosis
Updates in Osteoporosis Jeffrey A. Tice, MD Associate Professor of Medicine Division of General Internal Medicine, University of California, San Francisco I have no conflicts of interest What s New in
More informationOsteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017
Osteoporosis: How to Manage Long- Term Use of Bisphosphonates AKA Now What? David E Feinstein, DO, CCD November 15 th, 2017 Introduction A fracture due to OP occurs every 3 seconds around the world. 1
More informationMen and Osteoporosis So you think that it can t happen to you
Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School
More information2017 Hot topics in cardiometabolism: an interactive update
14-15 July, 2017 - Bogotà, Colombia 2017 Hot topics in cardiometabolism: an interactive update IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Nicola Napoli Department of Medicine,
More informationTrabecular Bone Score (TBS)
Trabecular Bone Score (TBS) From fracture prediction to clinical use Teheran May 2016 Prof. Didier Hans Center for Bone diseases, DAL Lausanne University Hospital, Switzerland didier.hans@ascendys.ch Osteoporosis
More informationDM and Osteoporosis. Why is it important?
DM and Osteoporosis Why is it important? Diabetes Osteoporosis Fractures Dr Pedro Conthe HGUGM Madrid Spain Agenda: DM and Osteoporosis Observational studies Physiopathology of bone Type I and Type 2 DM
More informationDr. Chih Hao Chen Ku, FACE Endocrinology Unit, San Juan de Dios Hospital Clinical Pharmacology and Toxicology Department, University of Costa Rica
Op*mizing biphosphonate therapy in osteoporosis Dr. Chih Hao Chen Ku, FACE Endocrinology Unit, San Juan de Dios Hospital Clinical Pharmacology and Toxicology Department, University of Costa Rica Conflicts
More informationMonitoring Osteoporosis Therapy
Monitoring Osteoporosis Therapy SUZANNE MORIN DEPT OF MEDICINE, DIVISION OF GENERAL INTERNAL MEDICINE, MUHC CENTRE FOR OUTCOMES RESEARCH AND EVALUATION, RI MUHC November 2017 Conflict of Interest Disclosures
More informationOsteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK
Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into
More informationOsteoporosis. Overview
v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)
More informationOsteoporosis Management
Osteoporosis Management Lisa Voss PA C, CCD Laura Frontiero NP C, CCD Kaiser Healthy Bones Program San Diego Disclosures: Nothing to disclose www.zazzle.com 1 Overview How to diagnose Osteoporosis FRAX
More informationASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction
Asian Spine Journal Asian Spine Clinical Journal Study Asian Spine J 2014;8(6):729-734 High http://dx.doi.org/10.4184/asj.2014.8.6.729 risk patients with osteopenia How Many High Risk Korean Patients with
More informationAn audit of osteoporotic patients in an Australian general practice
professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to
More informationLearning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.
12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn
More informationBuilding Bone Density-Research Issues
Building Bone Density-Research Issues Helping to Regain Bone Density QUESTION 1 What are the symptoms of Osteoporosis? Who is at risk? Symptoms Bone Fractures Osteoporosis 1,500,000 fractures a year Kyphosis
More informationPharmacy Management Drug Policy
SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage
More informationNAMS Practice Pearl. Use of Drug Holidays in Women Taking Bisphosphonates. Released April 1, 2013
NAMS Practice Pearl Use of Drug Holidays in Women Taking Bisphosphonates Released April 1, 2013 Dima L. Diab, MD 1, and Nelson B. Watts, MD 2 ( 1 Cincinnati VA Medical Center, Cincinnati, OH, 2 Mercy Health
More informationFracture=Bone Attack:
Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)
More informationMeta-analysis: analysis:
1 Diabetes and TZDs: Risk Factors for Fracture Ann Schwartz, PhD Dept. of Epidemiology and Biostatistics University of California San Francisco July 2010 Osteoporosis CME Presenter Disclosure Information
More informationOsteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018
Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy
More informationChanges in Skeletal Systems over the Lifespan. Connie M. Weaver, Ph.D. Purdue University
Changes in Skeletal Systems over the Lifespan Connie M. Weaver, Ph.D. Purdue University Disclosures Boards/Scientific Advisory Committees ILSI Showalter Pharmavite Grants NIH Dairy Research Institute Nestle
More informationNew 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS
New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance
More informationBAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008
BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology
More informationNIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.
NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk
More informationPractical Use of Decision Aids in Primary Care. Michael Soung, MD, FACP Virginia Mason Medical Center General Internal Medicine
Practical Use of Decision Aids in Primary Care Michael Soung, MD, FACP Virginia Mason Medical Center General Internal Medicine Question #1 40 yo man with total cholesterol 170, HDL 50, LDL 90. African
More informationCurrent Issues in Osteoporosis
Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,
More informationClinical Practice. Presented by: Internist, Endocrinologist
Clinical Practice Management of Osteoporosis Presented by: SaeedBehradmanesh, h MD Internist, Endocrinologist Iran, Isfahan, Feb. 2017 Definition: A disease characterized by low bone mass and microarchitectural
More informationsad EFFECTIVE DATE: POLICY LAST UPDATED:
Medical Coverage Policy Bone Mineral Density Studies sad EFFECTIVE DATE: 06 07 2011 POLICY LAST UPDATED: 11 06 2018 OVERVIEW Bone density studies can be used to identify individuals with osteoporosis and
More informationOsteoporosis: An Overview. Carolyn J. Crandall, MD, MS
Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis
More informationOriginal Article. Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT
Original Article Ramesh Keerthi Gadam, MD 1 ; Karen Schlauch, PhD 2 ; Kenneth E. Izuora, MD, MBA 1 ABSTRACT Objective: To compare Fracture Risk Assessment Tool (FRAX) calculations with and without bone
More informationRisk Factors for Postmenopausal Fractures What We Have Learned from The OSTPRE - study
Risk Factors for Postmenopausal Fractures What We Have Learned from The OSTPRE - study Heikki Kröger Kuopio Musculoskeletal Research Unit, University of Eastern Finland (UEF) Dept. of Orthopaedics, Traumatology
More informationBone Densitometry Pathway
Bone Densitometry Pathway The goal of the Bone Densitometry pathway is to manage our diagnosed osteopenic and osteoporotic patients, educate and monitor the patient population at risk for bone density
More informationParathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary
Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series
More informationAACE Congress Symposium Boston, MA May 20, 2018
Bone Loss After Bariatric Surgery: Causes, Consequences and Management John P. Bilezikian, MD, PhD(hon), MACE Silberberg Professor of Medicine Vice-Chair for International Education and Research Chief,
More informationOSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE. Lydia Au Geriatrics Ng Teng Fong Hospital
OSTEOPOROSIS AND WHAT TO DO AFTER A VERTEBRAL FRACTURE Lydia Au Geriatrics Ng Teng Fong Hospital LET S START WITH WHAT YOU WANT TO KNOW AND DO WITH A VERT FRACTURE Vertebral fractures Most common (550K
More informationNEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT
NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors
More informationOSTEOPOROSIS IN INDONESIA
OSTEOPOROSIS IN INDONESIA Hana Ratnawati Faculty of Medicine Maranatha Christian University Bandung - Indonesia 5th SBA Conference 2013 1 5th SBA Conference 2013 2 INTRODUCTION Indonesia is an archipelago
More informationSmoking is Associated with Increased Risk of Osteoporosis in Diabetes Mellitus Patients
Research Article imedpub Journals http://www.imedpub.com DOI: 10.4172/2469-6684.100031 Smoking is Associated with Increased Risk of Osteoporosis in Diabetes Mellitus Patients Tahir Alsaadawi Hilla Teaching
More informationDr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk
Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one
More informationObjectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING
Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify
More informationStudy of secondary causes of male osteoporosis
Study of secondary causes of male osteoporosis Suárez, S.M., Giunta J., Meneses G., Costanzo P.R., Knoblovits P. Department of Endocrinology, Metabolism and Nuclear Medicine of Hospital Italiano of Buenos
More informationOsteoporosis Medications: A Case-Based Discussion. Laila S. Tabatabai, MD August 5, 2017
Osteoporosis Medications: A Case-Based Discussion Laila S. Tabatabai, MD August 5, 2017 Disclosures Eli Lilly Radius Objectives Determine which patients with low bone density require treatment, along with
More informationCase Finding and Risk Assessment for Osteoporosis
Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors
More informationPharmacy Management Drug Policy
Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines
More informationKristen M. Nebel, DO PENN/ LGHP Geriatrics. Temple Family Medicine Review
Kristen M. Nebel, DO PENN/ LGHP Geriatrics 10/3/17 Temple Family Medicine Review OBJECTIVES Define Revised 2017 American College of Physician Recommendations Screening, Prevention and Treatment Application
More informationACP Colorado-Evidence Based Management of Osteoporosis
ACP Colorado-Evidence Based Management of Osteoporosis Micol S. Rothman, MD Associate Professor of Medicine and Radiology Clinical Director Metabolic Bone Program University of Colorado School of Medicine
More informationAACE/ACE Osteoporosis Treatment Decision Tool
AACE/ACE Osteoporosis Treatment Decision Tool What is Osteoporosis? OSTEOPOROSIS is defined as reduced bone strength leading to an increased risk of fracture. Osteoporosis, or porous bones, occurs when
More informationUse of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist
Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org
More informationDXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi
DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)
More informationValen&na Morelli, Cris&na Eller-Vainicher, Iacopo Chiodini,
PROPOSAL: Study on the effect of the shi6 from classic glucocor
More informationNew Osteoporosis Guidelines: What you and your health provider need to know QUESTION & ANSWER
The first of the newsletters on these Qs and As should include a refresher on the Virtual Forums what they are, how they work, etc. The fact is that less than 5% of COPN members tune in for any given Forum.
More informationT ype 1 diabetes (T1D) has been suggested. Prevalence of Morphometric Vertebral Fractures in Patients With Type 1 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Prevalence of Morphometric Vertebral Fractures in Patients With Type 1 Diabetes VOLHA V. ZHUKOUSKAYA, MD 1,2 CRISTINA ELLER-VAINICHER, MD 1 VOLHA
More informationBone Disorders in CKD
Osteoporosis in Dialysis Patients Challenges in Management David M. Klachko MD FACP Professor Emeritus of Medicine University of Missouri-Columbia Bone Disorders in CKD PTH-mediated high-turnover (osteitis
More informationOsteoporosis. When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of.
Osteoporosis When we talk about osteoporosis, we have to be familiar with the constituents of bone and what it is formed of. Osteoblasts by definition are those cells present in the bone and are involved
More informationOsteoporosis management in cancer patients
Osteoporosis management in cancer patients Belgian Menopause Society - Osteoporosis - Brussels, Oct 2017 Prof. JJ Body CHU Brugmann Univ. Libre de Bruxelles Brussels Bone loss associated with hormone ablation
More information9/9/2015 OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY DISCLOSURES
OSTEOPOROSIS WHAT S NEW AND ON THE HORIZON IN SCREENING, DRUG HOLIDAYS, SUPPLEMENTS, CONSERVATIVE THERAPY Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Stock options/holdings,
More informationAdvanced medicine conference. Monday 20 Tuesday 21 June 2016
Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus
More informationOsteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis
Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health
More information